nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PTGS2—skin cancer	0.5	1	CbGaD
Mesalazine—PPARG—dermis—skin cancer	0.00929	0.0751	CbGeAlD
Mesalazine—PPARG—leg—skin cancer	0.00613	0.0495	CbGeAlD
Mesalazine—PPARG—forelimb—skin cancer	0.00609	0.0492	CbGeAlD
Mesalazine—PPARG—hindlimb—skin cancer	0.00548	0.0442	CbGeAlD
Mesalazine—PPARG—appendage—skin cancer	0.0047	0.038	CbGeAlD
Mesalazine—MPO—endothelium—skin cancer	0.0032	0.0258	CbGeAlD
Mesalazine—CHUK—connective tissue—skin cancer	0.00317	0.0256	CbGeAlD
Mesalazine—PTGS2—leg—skin cancer	0.00313	0.0253	CbGeAlD
Mesalazine—IKBKB—nipple—skin cancer	0.00304	0.0245	CbGeAlD
Mesalazine—CHUK—epithelium—skin cancer	0.00301	0.0243	CbGeAlD
Mesalazine—MPO—blood vessel—skin cancer	0.00295	0.0238	CbGeAlD
Mesalazine—CHUK—skin of body—skin cancer	0.00286	0.0231	CbGeAlD
Mesalazine—PPARG—endothelium—skin cancer	0.00284	0.0229	CbGeAlD
Mesalazine—PTGS2—hindlimb—skin cancer	0.0028	0.0226	CbGeAlD
Mesalazine—PPARG—blood vessel—skin cancer	0.00262	0.0211	CbGeAlD
Mesalazine—PTGS2—appendage—skin cancer	0.0024	0.0194	CbGeAlD
Mesalazine—CHUK—lymphoid tissue—skin cancer	0.00232	0.0187	CbGeAlD
Mesalazine—CHUK—female reproductive system—skin cancer	0.00224	0.0181	CbGeAlD
Mesalazine—IKBKB—connective tissue—skin cancer	0.00216	0.0174	CbGeAlD
Mesalazine—PTGS2—skin epidermis—skin cancer	0.002	0.0161	CbGeAlD
Mesalazine—IKBKB—skin of body—skin cancer	0.00195	0.0157	CbGeAlD
Mesalazine—PPARG—nipple—skin cancer	0.00189	0.0153	CbGeAlD
Mesalazine—PPARG—neck—skin cancer	0.00187	0.0151	CbGeAlD
Mesalazine—CHUK—head—skin cancer	0.00187	0.0151	CbGeAlD
Mesalazine—ALOX5—connective tissue—skin cancer	0.00179	0.0144	CbGeAlD
Mesalazine—IKBKB—mammalian vulva—skin cancer	0.00177	0.0143	CbGeAlD
Mesalazine—IKBKB—lymphoid tissue—skin cancer	0.00158	0.0127	CbGeAlD
Mesalazine—IKBKB—female reproductive system—skin cancer	0.00152	0.0123	CbGeAlD
Mesalazine—PTGS1—endothelium—skin cancer	0.00152	0.0122	CbGeAlD
Mesalazine—MPO—connective tissue—skin cancer	0.00151	0.0122	CbGeAlD
Mesalazine—PTGS2—endothelium—skin cancer	0.00145	0.0117	CbGeAlD
Mesalazine—MPO—epithelium—skin cancer	0.00143	0.0116	CbGeAlD
Mesalazine—PTGS1—blood vessel—skin cancer	0.0014	0.0113	CbGeAlD
Mesalazine—MPO—skin of body—skin cancer	0.00136	0.011	CbGeAlD
Mesalazine—PPARG—connective tissue—skin cancer	0.00134	0.0108	CbGeAlD
Mesalazine—PTGS2—blood vessel—skin cancer	0.00134	0.0108	CbGeAlD
Mesalazine—CHUK—lymph node—skin cancer	0.00131	0.0106	CbGeAlD
Mesalazine—ALOX5—lymphoid tissue—skin cancer	0.00131	0.0106	CbGeAlD
Mesalazine—PPARG—epithelium—skin cancer	0.00127	0.0103	CbGeAlD
Mesalazine—IKBKB—head—skin cancer	0.00127	0.0103	CbGeAlD
Mesalazine—ALOX5—female reproductive system—skin cancer	0.00126	0.0102	CbGeAlD
Mesalazine—PPARG—skin of body—skin cancer	0.00121	0.00978	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS2—skin cancer	0.00117	0.3	CrCbGaD
Mesalazine—MPO—lymphoid tissue—skin cancer	0.00111	0.00893	CbGeAlD
Mesalazine—PPARG—mammalian vulva—skin cancer	0.0011	0.00892	CbGeAlD
Mesalazine—ALOX5—head—skin cancer	0.00105	0.0085	CbGeAlD
Mesalazine—PTGS1—nipple—skin cancer	0.00101	0.00817	CbGeAlD
Mesalazine—PPARG—lymphoid tissue—skin cancer	0.000981	0.00792	CbGeAlD
Mesalazine—PPARG—female reproductive system—skin cancer	0.000946	0.00764	CbGeAlD
Mesalazine—MPO—head—skin cancer	0.00089	0.00719	CbGeAlD
Mesalazine—IKBKB—lymph node—skin cancer	0.000889	0.00718	CbGeAlD
Mesalazine—Olsalazine—PTGS2—skin cancer	0.000803	0.206	CrCbGaD
Mesalazine—PPARG—head—skin cancer	0.00079	0.00638	CbGeAlD
Mesalazine—Diflunisal—PTGS2—skin cancer	0.000755	0.193	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS2—skin cancer	0.000755	0.193	CrCbGaD
Mesalazine—ALOX5—lymph node—skin cancer	0.000737	0.00595	CbGeAlD
Mesalazine—PTGS1—connective tissue—skin cancer	0.000717	0.00579	CbGeAlD
Mesalazine—PTGS2—connective tissue—skin cancer	0.000685	0.00554	CbGeAlD
Mesalazine—PTGS1—epithelium—skin cancer	0.000681	0.0055	CbGeAlD
Mesalazine—PTGS2—epithelium—skin cancer	0.000651	0.00526	CbGeAlD
Mesalazine—PTGS1—skin of body—skin cancer	0.000647	0.00523	CbGeAlD
Mesalazine—MPO—lymph node—skin cancer	0.000624	0.00504	CbGeAlD
Mesalazine—PTGS2—skin of body—skin cancer	0.000619	0.005	CbGeAlD
Mesalazine—PTGS1—mammalian vulva—skin cancer	0.00059	0.00477	CbGeAlD
Mesalazine—PPARG—lymph node—skin cancer	0.000553	0.00447	CbGeAlD
Mesalazine—PTGS1—female reproductive system—skin cancer	0.000506	0.00408	CbGeAlD
Mesalazine—PTGS2—lymphoid tissue—skin cancer	0.000501	0.00405	CbGeAlD
Mesalazine—PTGS2—female reproductive system—skin cancer	0.000483	0.0039	CbGeAlD
Mesalazine—PTGS1—head—skin cancer	0.000422	0.00341	CbGeAlD
Mesalazine—Salicylic acid—PTGS2—skin cancer	0.00042	0.108	CrCbGaD
Mesalazine—PTGS2—head—skin cancer	0.000404	0.00326	CbGeAlD
Mesalazine—PTGS1—lymph node—skin cancer	0.000296	0.00239	CbGeAlD
Mesalazine—PTGS2—lymph node—skin cancer	0.000283	0.00228	CbGeAlD
Mesalazine—Myalgia—Bleomycin—skin cancer	0.0002	0.000717	CcSEcCtD
Mesalazine—Abdominal pain upper—Docetaxel—skin cancer	0.0002	0.000716	CcSEcCtD
Mesalazine—Orthostatic hypotension—Docetaxel—skin cancer	0.0002	0.000716	CcSEcCtD
Mesalazine—Rash—Vemurafenib—skin cancer	0.0002	0.000715	CcSEcCtD
Mesalazine—Mental disorder—Temozolomide—skin cancer	0.0002	0.000715	CcSEcCtD
Mesalazine—Dermatitis—Vemurafenib—skin cancer	0.0002	0.000715	CcSEcCtD
Mesalazine—Hypersensitivity—Imiquimod—skin cancer	0.000199	0.000713	CcSEcCtD
Mesalazine—Headache—Vemurafenib—skin cancer	0.000198	0.000711	CcSEcCtD
Mesalazine—Erythema—Temozolomide—skin cancer	0.000198	0.00071	CcSEcCtD
Mesalazine—Breast disorder—Docetaxel—skin cancer	0.000198	0.000709	CcSEcCtD
Mesalazine—Discomfort—Bleomycin—skin cancer	0.000198	0.000708	CcSEcCtD
Mesalazine—Malaise—Dactinomycin—skin cancer	0.000198	0.000708	CcSEcCtD
Mesalazine—Cramp muscle—Docetaxel—skin cancer	0.000197	0.000706	CcSEcCtD
Mesalazine—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000197	0.000706	CcSEcCtD
Mesalazine—Leukopenia—Dactinomycin—skin cancer	0.000196	0.000703	CcSEcCtD
Mesalazine—Nasopharyngitis—Docetaxel—skin cancer	0.000196	0.000701	CcSEcCtD
Mesalazine—Dysgeusia—Temozolomide—skin cancer	0.000194	0.000696	CcSEcCtD
Mesalazine—Asthenia—Imiquimod—skin cancer	0.000194	0.000694	CcSEcCtD
Mesalazine—Confusional state—Bleomycin—skin cancer	0.000193	0.000693	CcSEcCtD
Mesalazine—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000193	0.000692	CcSEcCtD
Mesalazine—Oedema—Bleomycin—skin cancer	0.000192	0.000687	CcSEcCtD
Mesalazine—Anaphylactic shock—Bleomycin—skin cancer	0.000192	0.000687	CcSEcCtD
Mesalazine—Back pain—Temozolomide—skin cancer	0.000192	0.000687	CcSEcCtD
Mesalazine—Pruritus—Imiquimod—skin cancer	0.000191	0.000684	CcSEcCtD
Mesalazine—Infection—Bleomycin—skin cancer	0.000191	0.000683	CcSEcCtD
Mesalazine—Dysphagia—Docetaxel—skin cancer	0.000189	0.000678	CcSEcCtD
Mesalazine—Nausea—Vemurafenib—skin cancer	0.000188	0.000674	CcSEcCtD
Mesalazine—Thrombocytopenia—Bleomycin—skin cancer	0.000188	0.000673	CcSEcCtD
Mesalazine—Vision blurred—Temozolomide—skin cancer	0.000187	0.000669	CcSEcCtD
Mesalazine—Myalgia—Dactinomycin—skin cancer	0.000187	0.000669	CcSEcCtD
Mesalazine—Bronchospasm—Docetaxel—skin cancer	0.000186	0.000667	CcSEcCtD
Mesalazine—Tremor—Temozolomide—skin cancer	0.000186	0.000666	CcSEcCtD
Mesalazine—Alopecia—Fluorouracil—skin cancer	0.000186	0.000664	CcSEcCtD
Mesalazine—Diarrhoea—Imiquimod—skin cancer	0.000185	0.000662	CcSEcCtD
Mesalazine—Discomfort—Dactinomycin—skin cancer	0.000184	0.000661	CcSEcCtD
Mesalazine—Angina pectoris—Docetaxel—skin cancer	0.000184	0.00066	CcSEcCtD
Mesalazine—Ill-defined disorder—Temozolomide—skin cancer	0.000184	0.000659	CcSEcCtD
Mesalazine—Anaemia—Temozolomide—skin cancer	0.000183	0.000657	CcSEcCtD
Mesalazine—Anorexia—Bleomycin—skin cancer	0.000183	0.000655	CcSEcCtD
Mesalazine—Erythema—Fluorouracil—skin cancer	0.000183	0.000655	CcSEcCtD
Mesalazine—Angioedema—Temozolomide—skin cancer	0.000181	0.000649	CcSEcCtD
Mesalazine—Pancytopenia—Docetaxel—skin cancer	0.00018	0.000644	CcSEcCtD
Mesalazine—Hypotension—Bleomycin—skin cancer	0.000179	0.000642	CcSEcCtD
Mesalazine—Oedema—Dactinomycin—skin cancer	0.000179	0.000641	CcSEcCtD
Mesalazine—Malaise—Temozolomide—skin cancer	0.000179	0.000641	CcSEcCtD
Mesalazine—Dizziness—Imiquimod—skin cancer	0.000179	0.00064	CcSEcCtD
Mesalazine—Vertigo—Temozolomide—skin cancer	0.000178	0.000638	CcSEcCtD
Mesalazine—Infection—Dactinomycin—skin cancer	0.000178	0.000637	CcSEcCtD
Mesalazine—Leukopenia—Temozolomide—skin cancer	0.000178	0.000636	CcSEcCtD
Mesalazine—Neutropenia—Docetaxel—skin cancer	0.000177	0.000634	CcSEcCtD
Mesalazine—Palpitations—Temozolomide—skin cancer	0.000175	0.000628	CcSEcCtD
Mesalazine—Thrombocytopenia—Dactinomycin—skin cancer	0.000175	0.000628	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000175	0.000626	CcSEcCtD
Mesalazine—Cough—Temozolomide—skin cancer	0.000173	0.00062	CcSEcCtD
Mesalazine—Paraesthesia—Bleomycin—skin cancer	0.000172	0.000617	CcSEcCtD
Mesalazine—Weight increased—Docetaxel—skin cancer	0.000172	0.000617	CcSEcCtD
Mesalazine—Vision blurred—Fluorouracil—skin cancer	0.000172	0.000617	CcSEcCtD
Mesalazine—Vomiting—Imiquimod—skin cancer	0.000172	0.000615	CcSEcCtD
Mesalazine—Weight decreased—Docetaxel—skin cancer	0.000171	0.000613	CcSEcCtD
Mesalazine—Hypertension—Temozolomide—skin cancer	0.000171	0.000613	CcSEcCtD
Mesalazine—Dyspnoea—Bleomycin—skin cancer	0.000171	0.000613	CcSEcCtD
Mesalazine—Anorexia—Dactinomycin—skin cancer	0.000171	0.000611	CcSEcCtD
Mesalazine—Rash—Imiquimod—skin cancer	0.00017	0.00061	CcSEcCtD
Mesalazine—Dermatitis—Imiquimod—skin cancer	0.00017	0.000609	CcSEcCtD
Mesalazine—Pneumonia—Docetaxel—skin cancer	0.00017	0.000608	CcSEcCtD
Mesalazine—Headache—Imiquimod—skin cancer	0.000169	0.000606	CcSEcCtD
Mesalazine—Anaemia—Fluorouracil—skin cancer	0.000169	0.000605	CcSEcCtD
Mesalazine—Arthralgia—Temozolomide—skin cancer	0.000169	0.000605	CcSEcCtD
Mesalazine—Myalgia—Temozolomide—skin cancer	0.000169	0.000605	CcSEcCtD
Mesalazine—Infestation—Docetaxel—skin cancer	0.000169	0.000605	CcSEcCtD
Mesalazine—Infestation NOS—Docetaxel—skin cancer	0.000169	0.000605	CcSEcCtD
Mesalazine—Anxiety—Temozolomide—skin cancer	0.000168	0.000603	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000168	0.000601	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000167	0.000599	CcSEcCtD
Mesalazine—Discomfort—Temozolomide—skin cancer	0.000167	0.000598	CcSEcCtD
Mesalazine—Decreased appetite—Bleomycin—skin cancer	0.000167	0.000597	CcSEcCtD
Mesalazine—Renal failure—Docetaxel—skin cancer	0.000166	0.000594	CcSEcCtD
Mesalazine—Neuropathy peripheral—Docetaxel—skin cancer	0.000165	0.000593	CcSEcCtD
Mesalazine—Dry mouth—Temozolomide—skin cancer	0.000165	0.000591	CcSEcCtD
Mesalazine—Jaundice—Docetaxel—skin cancer	0.000165	0.000589	CcSEcCtD
Mesalazine—Stomatitis—Docetaxel—skin cancer	0.000165	0.000589	CcSEcCtD
Mesalazine—Pain—Bleomycin—skin cancer	0.000164	0.000588	CcSEcCtD
Mesalazine—Conjunctivitis—Docetaxel—skin cancer	0.000164	0.000588	CcSEcCtD
Mesalazine—Leukopenia—Fluorouracil—skin cancer	0.000164	0.000586	CcSEcCtD
Mesalazine—Confusional state—Temozolomide—skin cancer	0.000163	0.000585	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000163	0.000584	CcSEcCtD
Mesalazine—Anaphylactic shock—Temozolomide—skin cancer	0.000162	0.00058	CcSEcCtD
Mesalazine—Oedema—Temozolomide—skin cancer	0.000162	0.00058	CcSEcCtD
Mesalazine—Infection—Temozolomide—skin cancer	0.000161	0.000576	CcSEcCtD
Mesalazine—Nausea—Imiquimod—skin cancer	0.00016	0.000575	CcSEcCtD
Mesalazine—Hepatobiliary disease—Docetaxel—skin cancer	0.00016	0.000572	CcSEcCtD
Mesalazine—Epistaxis—Docetaxel—skin cancer	0.000159	0.00057	CcSEcCtD
Mesalazine—Nervous system disorder—Temozolomide—skin cancer	0.000159	0.000569	CcSEcCtD
Mesalazine—Thrombocytopenia—Temozolomide—skin cancer	0.000158	0.000568	CcSEcCtD
Mesalazine—Feeling abnormal—Bleomycin—skin cancer	0.000158	0.000566	CcSEcCtD
Mesalazine—Agranulocytosis—Docetaxel—skin cancer	0.000158	0.000564	CcSEcCtD
Mesalazine—Skin disorder—Temozolomide—skin cancer	0.000157	0.000563	CcSEcCtD
Mesalazine—Hyperhidrosis—Temozolomide—skin cancer	0.000156	0.00056	CcSEcCtD
Mesalazine—Chest pain—Fluorouracil—skin cancer	0.000156	0.000557	CcSEcCtD
Mesalazine—Myalgia—Fluorouracil—skin cancer	0.000156	0.000557	CcSEcCtD
Mesalazine—Decreased appetite—Dactinomycin—skin cancer	0.000156	0.000557	CcSEcCtD
Mesalazine—Fatigue—Dactinomycin—skin cancer	0.000154	0.000553	CcSEcCtD
Mesalazine—Anorexia—Temozolomide—skin cancer	0.000154	0.000553	CcSEcCtD
Mesalazine—Discomfort—Fluorouracil—skin cancer	0.000154	0.000551	CcSEcCtD
Mesalazine—Pain—Dactinomycin—skin cancer	0.000153	0.000548	CcSEcCtD
Mesalazine—Urticaria—Bleomycin—skin cancer	0.000152	0.000546	CcSEcCtD
Mesalazine—Haemoglobin—Docetaxel—skin cancer	0.000152	0.000545	CcSEcCtD
Mesalazine—Rhinitis—Docetaxel—skin cancer	0.000152	0.000544	CcSEcCtD
Mesalazine—Body temperature increased—Bleomycin—skin cancer	0.000152	0.000543	CcSEcCtD
Mesalazine—Hepatitis—Docetaxel—skin cancer	0.000152	0.000543	CcSEcCtD
Mesalazine—Haemorrhage—Docetaxel—skin cancer	0.000152	0.000543	CcSEcCtD
Mesalazine—Confusional state—Fluorouracil—skin cancer	0.00015	0.000539	CcSEcCtD
Mesalazine—Pharyngitis—Docetaxel—skin cancer	0.00015	0.000539	CcSEcCtD
Mesalazine—Urinary tract disorder—Docetaxel—skin cancer	0.00015	0.000536	CcSEcCtD
Mesalazine—Oedema peripheral—Docetaxel—skin cancer	0.000149	0.000535	CcSEcCtD
Mesalazine—Oedema—Fluorouracil—skin cancer	0.000149	0.000534	CcSEcCtD
Mesalazine—Anaphylactic shock—Fluorouracil—skin cancer	0.000149	0.000534	CcSEcCtD
Mesalazine—Connective tissue disorder—Docetaxel—skin cancer	0.000149	0.000533	CcSEcCtD
Mesalazine—Urethral disorder—Docetaxel—skin cancer	0.000149	0.000532	CcSEcCtD
Mesalazine—Infection—Fluorouracil—skin cancer	0.000148	0.000531	CcSEcCtD
Mesalazine—Feeling abnormal—Dactinomycin—skin cancer	0.000147	0.000528	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000147	0.000528	CcSEcCtD
Mesalazine—Insomnia—Temozolomide—skin cancer	0.000146	0.000524	CcSEcCtD
Mesalazine—Gastrointestinal pain—Dactinomycin—skin cancer	0.000146	0.000524	CcSEcCtD
Mesalazine—Nervous system disorder—Fluorouracil—skin cancer	0.000146	0.000524	CcSEcCtD
Mesalazine—Thrombocytopenia—Fluorouracil—skin cancer	0.000146	0.000523	CcSEcCtD
Mesalazine—Tachycardia—Fluorouracil—skin cancer	0.000146	0.000521	CcSEcCtD
Mesalazine—Paraesthesia—Temozolomide—skin cancer	0.000145	0.000521	CcSEcCtD
Mesalazine—Dyspnoea—Temozolomide—skin cancer	0.000144	0.000517	CcSEcCtD
Mesalazine—Somnolence—Temozolomide—skin cancer	0.000144	0.000515	CcSEcCtD
Mesalazine—Erythema multiforme—Docetaxel—skin cancer	0.000143	0.000513	CcSEcCtD
Mesalazine—Dyspepsia—Temozolomide—skin cancer	0.000142	0.00051	CcSEcCtD
Mesalazine—Anorexia—Fluorouracil—skin cancer	0.000142	0.000509	CcSEcCtD
Mesalazine—Eye disorder—Docetaxel—skin cancer	0.000142	0.000507	CcSEcCtD
Mesalazine—Abdominal pain—Dactinomycin—skin cancer	0.000141	0.000507	CcSEcCtD
Mesalazine—Body temperature increased—Dactinomycin—skin cancer	0.000141	0.000507	CcSEcCtD
Mesalazine—Hypersensitivity—Bleomycin—skin cancer	0.000141	0.000506	CcSEcCtD
Mesalazine—Decreased appetite—Temozolomide—skin cancer	0.000141	0.000504	CcSEcCtD
Mesalazine—Cardiac disorder—Docetaxel—skin cancer	0.000141	0.000504	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Temozolomide—skin cancer	0.00014	0.000501	CcSEcCtD
Mesalazine—Fatigue—Temozolomide—skin cancer	0.00014	0.0005	CcSEcCtD
Mesalazine—Hypotension—Fluorouracil—skin cancer	0.000139	0.000499	CcSEcCtD
Mesalazine—Pain—Temozolomide—skin cancer	0.000138	0.000496	CcSEcCtD
Mesalazine—Constipation—Temozolomide—skin cancer	0.000138	0.000496	CcSEcCtD
Mesalazine—Asthenia—Bleomycin—skin cancer	0.000138	0.000493	CcSEcCtD
Mesalazine—Angiopathy—Docetaxel—skin cancer	0.000137	0.000492	CcSEcCtD
Mesalazine—Immune system disorder—Docetaxel—skin cancer	0.000137	0.00049	CcSEcCtD
Mesalazine—Mediastinal disorder—Docetaxel—skin cancer	0.000137	0.000489	CcSEcCtD
Mesalazine—Chills—Docetaxel—skin cancer	0.000136	0.000487	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000136	0.000487	CcSEcCtD
Mesalazine—Pruritus—Bleomycin—skin cancer	0.000136	0.000486	CcSEcCtD
Mesalazine—Insomnia—Fluorouracil—skin cancer	0.000135	0.000483	CcSEcCtD
Mesalazine—Paraesthesia—Fluorouracil—skin cancer	0.000134	0.00048	CcSEcCtD
Mesalazine—Alopecia—Docetaxel—skin cancer	0.000134	0.00048	CcSEcCtD
Mesalazine—Feeling abnormal—Temozolomide—skin cancer	0.000133	0.000478	CcSEcCtD
Mesalazine—Dyspnoea—Fluorouracil—skin cancer	0.000133	0.000476	CcSEcCtD
Mesalazine—Mental disorder—Docetaxel—skin cancer	0.000133	0.000475	CcSEcCtD
Mesalazine—Somnolence—Fluorouracil—skin cancer	0.000133	0.000475	CcSEcCtD
Mesalazine—Gastrointestinal pain—Temozolomide—skin cancer	0.000132	0.000474	CcSEcCtD
Mesalazine—Erythema—Docetaxel—skin cancer	0.000132	0.000472	CcSEcCtD
Mesalazine—Hypersensitivity—Dactinomycin—skin cancer	0.000132	0.000472	CcSEcCtD
Mesalazine—Dyspepsia—Fluorouracil—skin cancer	0.000131	0.00047	CcSEcCtD
Mesalazine—Decreased appetite—Fluorouracil—skin cancer	0.00013	0.000464	CcSEcCtD
Mesalazine—Dysgeusia—Docetaxel—skin cancer	0.000129	0.000463	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000129	0.000461	CcSEcCtD
Mesalazine—Urticaria—Temozolomide—skin cancer	0.000129	0.000461	CcSEcCtD
Mesalazine—Asthenia—Dactinomycin—skin cancer	0.000128	0.00046	CcSEcCtD
Mesalazine—Abdominal pain—Temozolomide—skin cancer	0.000128	0.000458	CcSEcCtD
Mesalazine—Body temperature increased—Temozolomide—skin cancer	0.000128	0.000458	CcSEcCtD
Mesalazine—Back pain—Docetaxel—skin cancer	0.000128	0.000457	CcSEcCtD
Mesalazine—Pain—Fluorouracil—skin cancer	0.000128	0.000457	CcSEcCtD
Mesalazine—Muscle spasms—Docetaxel—skin cancer	0.000127	0.000454	CcSEcCtD
Mesalazine—Feeling abnormal—Fluorouracil—skin cancer	0.000123	0.00044	CcSEcCtD
Mesalazine—Diarrhoea—Dactinomycin—skin cancer	0.000122	0.000439	CcSEcCtD
Mesalazine—Vomiting—Bleomycin—skin cancer	0.000122	0.000437	CcSEcCtD
Mesalazine—Anaemia—Docetaxel—skin cancer	0.000122	0.000437	CcSEcCtD
Mesalazine—Rash—Bleomycin—skin cancer	0.000121	0.000433	CcSEcCtD
Mesalazine—Dermatitis—Bleomycin—skin cancer	0.000121	0.000433	CcSEcCtD
Mesalazine—Hypersensitivity—Temozolomide—skin cancer	0.000119	0.000427	CcSEcCtD
Mesalazine—Urticaria—Fluorouracil—skin cancer	0.000118	0.000424	CcSEcCtD
Mesalazine—Syncope—Docetaxel—skin cancer	0.000118	0.000424	CcSEcCtD
Mesalazine—Leukopenia—Docetaxel—skin cancer	0.000118	0.000423	CcSEcCtD
Mesalazine—Body temperature increased—Fluorouracil—skin cancer	0.000118	0.000422	CcSEcCtD
Mesalazine—Palpitations—Docetaxel—skin cancer	0.000117	0.000417	CcSEcCtD
Mesalazine—Asthenia—Temozolomide—skin cancer	0.000116	0.000416	CcSEcCtD
Mesalazine—Loss of consciousness—Docetaxel—skin cancer	0.000116	0.000415	CcSEcCtD
Mesalazine—Cough—Docetaxel—skin cancer	0.000115	0.000412	CcSEcCtD
Mesalazine—Pruritus—Temozolomide—skin cancer	0.000115	0.00041	CcSEcCtD
Mesalazine—Nausea—Bleomycin—skin cancer	0.000114	0.000408	CcSEcCtD
Mesalazine—Hypertension—Docetaxel—skin cancer	0.000114	0.000408	CcSEcCtD
Mesalazine—Vomiting—Dactinomycin—skin cancer	0.000114	0.000408	CcSEcCtD
Mesalazine—Rash—Dactinomycin—skin cancer	0.000113	0.000404	CcSEcCtD
Mesalazine—Arthralgia—Docetaxel—skin cancer	0.000112	0.000402	CcSEcCtD
Mesalazine—Chest pain—Docetaxel—skin cancer	0.000112	0.000402	CcSEcCtD
Mesalazine—Myalgia—Docetaxel—skin cancer	0.000112	0.000402	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000112	0.000399	CcSEcCtD
Mesalazine—Diarrhoea—Temozolomide—skin cancer	0.000111	0.000397	CcSEcCtD
Mesalazine—Hypersensitivity—Fluorouracil—skin cancer	0.00011	0.000394	CcSEcCtD
Mesalazine—Dry mouth—Docetaxel—skin cancer	0.00011	0.000393	CcSEcCtD
Mesalazine—Confusional state—Docetaxel—skin cancer	0.000109	0.000389	CcSEcCtD
Mesalazine—Oedema—Docetaxel—skin cancer	0.000108	0.000386	CcSEcCtD
Mesalazine—Anaphylactic shock—Docetaxel—skin cancer	0.000108	0.000386	CcSEcCtD
Mesalazine—Dizziness—Temozolomide—skin cancer	0.000107	0.000383	CcSEcCtD
Mesalazine—Infection—Docetaxel—skin cancer	0.000107	0.000383	CcSEcCtD
Mesalazine—Nausea—Dactinomycin—skin cancer	0.000106	0.000381	CcSEcCtD
Mesalazine—Shock—Docetaxel—skin cancer	0.000106	0.000379	CcSEcCtD
Mesalazine—Nervous system disorder—Docetaxel—skin cancer	0.000106	0.000378	CcSEcCtD
Mesalazine—Pruritus—Fluorouracil—skin cancer	0.000106	0.000378	CcSEcCtD
Mesalazine—Thrombocytopenia—Docetaxel—skin cancer	0.000105	0.000377	CcSEcCtD
Mesalazine—IKBKB—Signaling by Interleukins—KRAS—skin cancer	0.000105	0.00113	CbGpPWpGaD
Mesalazine—Tachycardia—Docetaxel—skin cancer	0.000105	0.000376	CcSEcCtD
Mesalazine—Skin disorder—Docetaxel—skin cancer	0.000105	0.000374	CcSEcCtD
Mesalazine—CHUK—Downstream signaling of activated FGFR—NRAS—skin cancer	0.000104	0.00112	CbGpPWpGaD
Mesalazine—IKBKB—MyD88 cascade initiated on plasma membrane—IL6—skin cancer	0.000104	0.00111	CbGpPWpGaD
Mesalazine—IKBKB—TCR Signaling Pathway—HRAS—skin cancer	0.000103	0.00111	CbGpPWpGaD
Mesalazine—CHUK—Disease—CSPG4—skin cancer	0.000103	0.0011	CbGpPWpGaD
Mesalazine—Vomiting—Temozolomide—skin cancer	0.000103	0.000369	CcSEcCtD
Mesalazine—IKBKB—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—skin cancer	0.000103	0.0011	CbGpPWpGaD
Mesalazine—Anorexia—Docetaxel—skin cancer	0.000103	0.000368	CcSEcCtD
Mesalazine—CHUK—Signaling by ERBB4—NRAS—skin cancer	0.000102	0.0011	CbGpPWpGaD
Mesalazine—Rash—Temozolomide—skin cancer	0.000102	0.000366	CcSEcCtD
Mesalazine—Diarrhoea—Fluorouracil—skin cancer	0.000102	0.000365	CcSEcCtD
Mesalazine—Dermatitis—Temozolomide—skin cancer	0.000102	0.000365	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—FOXO4—skin cancer	0.000102	0.00109	CbGpPWpGaD
Mesalazine—IKBKB—TNF alpha Signaling Pathway—HRAS—skin cancer	0.000102	0.00109	CbGpPWpGaD
Mesalazine—Headache—Temozolomide—skin cancer	0.000101	0.000363	CcSEcCtD
Mesalazine—CHUK—MyD88-independent cascade—IL6—skin cancer	0.000101	0.00108	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—ENO2—skin cancer	0.000101	0.00108	CbGpPWpGaD
Mesalazine—IKBKB—MyD88 dependent cascade initiated on endosome—IL6—skin cancer	0.000101	0.00108	CbGpPWpGaD
Mesalazine—Hypotension—Docetaxel—skin cancer	0.000101	0.00036	CcSEcCtD
Mesalazine—IKBKB—TCR Signaling Pathway—IL6—skin cancer	9.9e-05	0.00106	CbGpPWpGaD
Mesalazine—CHUK—Toll-like Receptor Signaling Pathway—IL6—skin cancer	9.87e-05	0.00106	CbGpPWpGaD
Mesalazine—Dizziness—Fluorouracil—skin cancer	9.86e-05	0.000353	CcSEcCtD
Mesalazine—CHUK—Signaling by Interleukins—HRAS—skin cancer	9.86e-05	0.00106	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—BRAF—skin cancer	9.84e-05	0.00105	CbGpPWpGaD
Mesalazine—Musculoskeletal discomfort—Docetaxel—skin cancer	9.81e-05	0.000351	CcSEcCtD
Mesalazine—CHUK—Downstream signal transduction—NRAS—skin cancer	9.79e-05	0.00105	CbGpPWpGaD
Mesalazine—PTGS2—C-MYB transcription factor network—NRAS—skin cancer	9.76e-05	0.00105	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR—NRAS—skin cancer	9.74e-05	0.00104	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Receptor Signaling Pathway—HRAS—skin cancer	9.74e-05	0.00104	CbGpPWpGaD
Mesalazine—Insomnia—Docetaxel—skin cancer	9.74e-05	0.000349	CcSEcCtD
Mesalazine—IKBKB—TNF alpha Signaling Pathway—IL6—skin cancer	9.72e-05	0.00104	CbGpPWpGaD
Mesalazine—IKBKB—Toll Like Receptor 9 (TLR9) Cascade—IL6—skin cancer	9.72e-05	0.00104	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—NRAS—skin cancer	9.69e-05	0.00104	CbGpPWpGaD
Mesalazine—Paraesthesia—Docetaxel—skin cancer	9.67e-05	0.000346	CcSEcCtD
Mesalazine—CHUK—DAP12 signaling—NRAS—skin cancer	9.64e-05	0.00103	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—FOXO4—skin cancer	9.62e-05	0.00103	CbGpPWpGaD
Mesalazine—Nausea—Temozolomide—skin cancer	9.61e-05	0.000344	CcSEcCtD
Mesalazine—Dyspnoea—Docetaxel—skin cancer	9.6e-05	0.000344	CcSEcCtD
Mesalazine—Somnolence—Docetaxel—skin cancer	9.57e-05	0.000343	CcSEcCtD
Mesalazine—IKBKB—MyD88:Mal cascade initiated on plasma membrane—IL6—skin cancer	9.56e-05	0.00102	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTCH2—skin cancer	9.51e-05	0.00102	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—NRAS—skin cancer	9.51e-05	0.00102	CbGpPWpGaD
Mesalazine—Vomiting—Fluorouracil—skin cancer	9.48e-05	0.00034	CcSEcCtD
Mesalazine—Dyspepsia—Docetaxel—skin cancer	9.48e-05	0.000339	CcSEcCtD
Mesalazine—CHUK—Signaling by Interleukins—IL6—skin cancer	9.43e-05	0.00101	CbGpPWpGaD
Mesalazine—Rash—Fluorouracil—skin cancer	9.4e-05	0.000337	CcSEcCtD
Mesalazine—Dermatitis—Fluorouracil—skin cancer	9.4e-05	0.000336	CcSEcCtD
Mesalazine—CHUK—Signaling by SCF-KIT—KRAS—skin cancer	9.37e-05	0.001	CbGpPWpGaD
Mesalazine—Decreased appetite—Docetaxel—skin cancer	9.36e-05	0.000335	CcSEcCtD
Mesalazine—Headache—Fluorouracil—skin cancer	9.34e-05	0.000335	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Docetaxel—skin cancer	9.29e-05	0.000333	CcSEcCtD
Mesalazine—Fatigue—Docetaxel—skin cancer	9.28e-05	0.000332	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—FOXO4—skin cancer	9.23e-05	0.00099	CbGpPWpGaD
Mesalazine—Pain—Docetaxel—skin cancer	9.21e-05	0.00033	CcSEcCtD
Mesalazine—Constipation—Docetaxel—skin cancer	9.21e-05	0.00033	CcSEcCtD
Mesalazine—PPARG—Metabolism—CSPG4—skin cancer	9.18e-05	0.000984	CbGpPWpGaD
Mesalazine—IKBKB—MyD88-independent cascade—IL6—skin cancer	9.17e-05	0.000983	CbGpPWpGaD
Mesalazine—CHUK—Activated TLR4 signalling—IL6—skin cancer	9.1e-05	0.000975	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	9.09e-05	0.000975	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	9.07e-05	0.000973	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—NRAS—skin cancer	9.07e-05	0.000973	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—NRAS—skin cancer	9.07e-05	0.000973	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—NRAS—skin cancer	8.99e-05	0.000964	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling of activated FGFR—KRAS—skin cancer	8.96e-05	0.000961	CbGpPWpGaD
Mesalazine—IKBKB—Toll-like Receptor Signaling Pathway—IL6—skin cancer	8.95e-05	0.00096	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by Interleukins—HRAS—skin cancer	8.94e-05	0.000958	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—BRAF—skin cancer	8.92e-05	0.000956	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—NRAS—skin cancer	8.91e-05	0.000956	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—NRAS—skin cancer	8.87e-05	0.000951	CbGpPWpGaD
Mesalazine—Feeling abnormal—Docetaxel—skin cancer	8.87e-05	0.000318	CcSEcCtD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—KRAS—skin cancer	8.87e-05	0.000951	CbGpPWpGaD
Mesalazine—Nausea—Fluorouracil—skin cancer	8.86e-05	0.000317	CcSEcCtD
Mesalazine—CHUK—Signaling by ERBB4—KRAS—skin cancer	8.82e-05	0.000946	CbGpPWpGaD
Mesalazine—Gastrointestinal pain—Docetaxel—skin cancer	8.8e-05	0.000315	CcSEcCtD
Mesalazine—PPARG—Adipogenesis—IL6—skin cancer	8.66e-05	0.000929	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTCH2—skin cancer	8.62e-05	0.000924	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—NRAS—skin cancer	8.62e-05	0.000924	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—NRAS—skin cancer	8.58e-05	0.00092	CbGpPWpGaD
Mesalazine—CHUK—Toll Like Receptor 4 (TLR4) Cascade—IL6—skin cancer	8.56e-05	0.000917	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by Interleukins—IL6—skin cancer	8.55e-05	0.000917	CbGpPWpGaD
Mesalazine—Abdominal pain—Docetaxel—skin cancer	8.51e-05	0.000305	CcSEcCtD
Mesalazine—Body temperature increased—Docetaxel—skin cancer	8.51e-05	0.000305	CcSEcCtD
Mesalazine—CHUK—Downstream signal transduction—KRAS—skin cancer	8.42e-05	0.000903	CbGpPWpGaD
Mesalazine—PTGS2—C-MYB transcription factor network—KRAS—skin cancer	8.4e-05	0.0009	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—NRAS—skin cancer	8.4e-05	0.0009	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR—KRAS—skin cancer	8.38e-05	0.000899	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—KRAS—skin cancer	8.34e-05	0.000894	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—KRAS—skin cancer	8.3e-05	0.00089	CbGpPWpGaD
Mesalazine—PTGS1—Selenium Micronutrient Network—IL6—skin cancer	8.29e-05	0.000889	CbGpPWpGaD
Mesalazine—IKBKB—Activated TLR4 signalling—IL6—skin cancer	8.25e-05	0.000884	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	8.23e-05	0.000882	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—KRAS—skin cancer	8.18e-05	0.000877	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	8.04e-05	0.000862	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PLIN2—skin cancer	7.98e-05	0.000855	CbGpPWpGaD
Mesalazine—CHUK—Signaling by SCF-KIT—HRAS—skin cancer	7.96e-05	0.000854	CbGpPWpGaD
Mesalazine—Hypersensitivity—Docetaxel—skin cancer	7.93e-05	0.000284	CcSEcCtD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	7.89e-05	0.000845	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—TP53—skin cancer	7.88e-05	0.000845	CbGpPWpGaD
Mesalazine—CHUK—BDNF signaling pathway—HRAS—skin cancer	7.83e-05	0.000839	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	7.81e-05	0.000837	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—KRAS—skin cancer	7.81e-05	0.000837	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—KRAS—skin cancer	7.81e-05	0.000837	CbGpPWpGaD
Mesalazine—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—IL6—skin cancer	7.76e-05	0.000832	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—KRAS—skin cancer	7.74e-05	0.00083	CbGpPWpGaD
Mesalazine—Asthenia—Docetaxel—skin cancer	7.72e-05	0.000277	CcSEcCtD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—IL6—skin cancer	7.71e-05	0.000826	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—KRAS—skin cancer	7.67e-05	0.000822	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—CDK4—skin cancer	7.65e-05	0.00082	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—KRAS—skin cancer	7.64e-05	0.000819	CbGpPWpGaD
Mesalazine—CHUK—Toll-Like Receptors Cascades—IL6—skin cancer	7.62e-05	0.000817	CbGpPWpGaD
Mesalazine—CHUK—Signaling by SCF-KIT—IL6—skin cancer	7.62e-05	0.000817	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling of activated FGFR—HRAS—skin cancer	7.62e-05	0.000817	CbGpPWpGaD
Mesalazine—Pruritus—Docetaxel—skin cancer	7.62e-05	0.000273	CcSEcCtD
Mesalazine—IKBKB—B Cell Activation—NRAS—skin cancer	7.61e-05	0.000816	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB4—HRAS—skin cancer	7.5e-05	0.000804	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—KRAS—skin cancer	7.42e-05	0.000795	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—KRAS—skin cancer	7.38e-05	0.000792	CbGpPWpGaD
Mesalazine—Diarrhoea—Docetaxel—skin cancer	7.37e-05	0.000264	CcSEcCtD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	7.35e-05	0.000788	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling of activated FGFR—IL6—skin cancer	7.29e-05	0.000782	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—KRAS—skin cancer	7.23e-05	0.000775	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—GLI2—skin cancer	7.21e-05	0.000773	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB4—IL6—skin cancer	7.18e-05	0.000769	CbGpPWpGaD
Mesalazine—CHUK—Downstream signal transduction—HRAS—skin cancer	7.16e-05	0.000768	CbGpPWpGaD
Mesalazine—PTGS2—C-MYB transcription factor network—HRAS—skin cancer	7.14e-05	0.000765	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR—HRAS—skin cancer	7.13e-05	0.000764	CbGpPWpGaD
Mesalazine—Dizziness—Docetaxel—skin cancer	7.12e-05	0.000255	CcSEcCtD
Mesalazine—IKBKB—BDNF signaling pathway—HRAS—skin cancer	7.1e-05	0.000761	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—HRAS—skin cancer	7.09e-05	0.00076	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	7.08e-05	0.000759	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—HRAS—skin cancer	7.06e-05	0.000756	CbGpPWpGaD
Mesalazine—CHUK—Disease—SHH—skin cancer	7e-05	0.00075	CbGpPWpGaD
Mesalazine—CHUK—Disease—ENO2—skin cancer	7e-05	0.00075	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—IL6—skin cancer	6.99e-05	0.000749	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	6.95e-05	0.000746	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	6.92e-05	0.000742	CbGpPWpGaD
Mesalazine—IKBKB—Toll-Like Receptors Cascades—IL6—skin cancer	6.91e-05	0.000741	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MC1R—skin cancer	6.88e-05	0.000737	CbGpPWpGaD
Mesalazine—CHUK—Downstream signal transduction—IL6—skin cancer	6.85e-05	0.000735	CbGpPWpGaD
Mesalazine—Vomiting—Docetaxel—skin cancer	6.84e-05	0.000245	CcSEcCtD
Mesalazine—CHUK—Signaling by FGFR—IL6—skin cancer	6.82e-05	0.000731	CbGpPWpGaD
Mesalazine—Rash—Docetaxel—skin cancer	6.79e-05	0.000243	CcSEcCtD
Mesalazine—CHUK—Signaling by ERBB2—IL6—skin cancer	6.79e-05	0.000728	CbGpPWpGaD
Mesalazine—Dermatitis—Docetaxel—skin cancer	6.78e-05	0.000243	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—GLI1—skin cancer	6.78e-05	0.000726	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—IL6—skin cancer	6.75e-05	0.000724	CbGpPWpGaD
Mesalazine—Headache—Docetaxel—skin cancer	6.74e-05	0.000242	CcSEcCtD
Mesalazine—PPARG—Circadian rythm related genes—TP53—skin cancer	6.68e-05	0.000716	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	6.64e-05	0.000712	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—HRAS—skin cancer	6.64e-05	0.000712	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—HRAS—skin cancer	6.64e-05	0.000712	CbGpPWpGaD
Mesalazine—PTGS2—Selenium Micronutrient Network—IL6—skin cancer	6.58e-05	0.000706	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—HRAS—skin cancer	6.58e-05	0.000705	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—TP53—skin cancer	6.56e-05	0.000704	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—KRAS—skin cancer	6.55e-05	0.000703	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GLI2—skin cancer	6.54e-05	0.000701	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	6.53e-05	0.0007	CbGpPWpGaD
Mesalazine—IKBKB—Insulin Signaling—HRAS—skin cancer	6.53e-05	0.0007	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—HRAS—skin cancer	6.52e-05	0.000699	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—HRAS—skin cancer	6.49e-05	0.000696	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CSPG4—skin cancer	6.43e-05	0.000689	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SUFU—skin cancer	6.42e-05	0.000689	CbGpPWpGaD
Mesalazine—Nausea—Docetaxel—skin cancer	6.39e-05	0.000229	CcSEcCtD
Mesalazine—CHUK—DAP12 interactions—IL6—skin cancer	6.35e-05	0.000681	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—IL6—skin cancer	6.35e-05	0.000681	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	6.35e-05	0.000681	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PLIN2—skin cancer	6.33e-05	0.000679	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	6.31e-05	0.000676	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—IL6—skin cancer	6.3e-05	0.000675	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—NRAS—skin cancer	6.29e-05	0.000674	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ENO2—skin cancer	6.24e-05	0.000669	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—IL6—skin cancer	6.24e-05	0.000669	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MC1R—skin cancer	6.23e-05	0.000668	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—IL6—skin cancer	6.21e-05	0.000666	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—NRAS—skin cancer	6.18e-05	0.000663	CbGpPWpGaD
Mesalazine—CHUK—Immune System—FOXO4—skin cancer	6.18e-05	0.000662	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GLI1—skin cancer	6.14e-05	0.000659	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—HRAS—skin cancer	6.14e-05	0.000659	CbGpPWpGaD
Mesalazine—PPARG—Circadian rythm related genes—IL6—skin cancer	6.11e-05	0.000655	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CSPG4—skin cancer	6.1e-05	0.000654	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	6.02e-05	0.000645	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	5.88e-05	0.00063	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—ERCC2—skin cancer	5.86e-05	0.000628	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SUFU—skin cancer	5.82e-05	0.000624	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	5.76e-05	0.000618	CbGpPWpGaD
Mesalazine—CHUK—Disease—FOXO4—skin cancer	5.7e-05	0.000611	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—NRAS—skin cancer	5.7e-05	0.000611	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TP53—skin cancer	5.69e-05	0.00061	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	5.63e-05	0.000603	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—NRAS—skin cancer	5.6e-05	0.000601	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—FOXO4—skin cancer	5.6e-05	0.0006	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—HRAS—skin cancer	5.57e-05	0.000597	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—KRAS—skin cancer	5.41e-05	0.00058	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—KRAS—skin cancer	5.32e-05	0.00057	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—IL6—skin cancer	5.21e-05	0.000558	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CSPG4—skin cancer	5.11e-05	0.000547	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—KRAS—skin cancer	4.91e-05	0.000526	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SHH—skin cancer	4.9e-05	0.000525	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.88e-05	0.000523	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RASA1—skin cancer	4.87e-05	0.000522	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—KRAS—skin cancer	4.82e-05	0.000517	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—ERCC2—skin cancer	4.66e-05	0.0005	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTCH1—skin cancer	4.64e-05	0.000498	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SMO—skin cancer	4.64e-05	0.000498	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—HRAS—skin cancer	4.6e-05	0.000493	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—HRAS—skin cancer	4.52e-05	0.000485	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTGER4—skin cancer	4.52e-05	0.000485	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SHH—skin cancer	4.44e-05	0.000476	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RASA1—skin cancer	4.41e-05	0.000473	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IL6—skin cancer	4.4e-05	0.000472	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ENO2—skin cancer	4.37e-05	0.000469	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	4.35e-05	0.000467	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—IL6—skin cancer	4.33e-05	0.000464	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—NRAS—skin cancer	4.25e-05	0.000456	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTCH1—skin cancer	4.21e-05	0.000451	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SMO—skin cancer	4.21e-05	0.000451	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—HRAS—skin cancer	4.17e-05	0.000447	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SHH—skin cancer	4.14e-05	0.000444	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ENO2—skin cancer	4.14e-05	0.000444	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—HRAS—skin cancer	4.1e-05	0.00044	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTGER4—skin cancer	4.1e-05	0.00044	CbGpPWpGaD
Mesalazine—CHUK—Disease—ERCC2—skin cancer	4.06e-05	0.000436	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FOXO4—skin cancer	3.99e-05	0.000428	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IL6—skin cancer	3.99e-05	0.000428	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—IL6—skin cancer	3.92e-05	0.000421	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	3.87e-05	0.000415	CbGpPWpGaD
Mesalazine—CHUK—Disease—TERT—skin cancer	3.81e-05	0.000408	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—KRAS—skin cancer	3.66e-05	0.000392	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ERCC2—skin cancer	3.63e-05	0.000389	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FOXO4—skin cancer	3.62e-05	0.000388	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—NRAS—skin cancer	3.53e-05	0.000378	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTGS2—skin cancer	3.51e-05	0.000376	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ENO2—skin cancer	3.47e-05	0.000372	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.42e-05	0.000367	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—NRAS—skin cancer	3.39e-05	0.000363	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FOXO4—skin cancer	3.38e-05	0.000362	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—NRAS—skin cancer	3.2e-05	0.000343	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—HRAS—skin cancer	3.11e-05	0.000333	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—NRAS—skin cancer	3.07e-05	0.000329	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—KRAS—skin cancer	3.03e-05	0.000325	CbGpPWpGaD
Mesalazine—CHUK—Disease—BRAF—skin cancer	3.02e-05	0.000323	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—IL6—skin cancer	2.98e-05	0.000319	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—KRAS—skin cancer	2.91e-05	0.000312	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—KRAS—skin cancer	2.75e-05	0.000295	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TERT—skin cancer	2.67e-05	0.000286	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—KRAS—skin cancer	2.64e-05	0.000283	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—HRAS—skin cancer	2.58e-05	0.000277	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ERCC2—skin cancer	2.54e-05	0.000272	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HRAS—skin cancer	2.48e-05	0.000266	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IL6—skin cancer	2.47e-05	0.000265	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—skin cancer	2.44e-05	0.000261	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TERT—skin cancer	2.42e-05	0.000259	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERCC2—skin cancer	2.41e-05	0.000258	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HRAS—skin cancer	2.34e-05	0.000251	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TERT—skin cancer	2.26e-05	0.000242	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HRAS—skin cancer	2.25e-05	0.000241	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IL6—skin cancer	2.24e-05	0.00024	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—skin cancer	2.17e-05	0.000233	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—BRAF—skin cancer	2.11e-05	0.000226	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NRAS—skin cancer	2.05e-05	0.00022	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ERCC2—skin cancer	2.02e-05	0.000216	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—BRAF—skin cancer	1.92e-05	0.000205	CbGpPWpGaD
Mesalazine—CHUK—Disease—NRAS—skin cancer	1.9e-05	0.000203	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NRAS—skin cancer	1.86e-05	0.0002	CbGpPWpGaD
Mesalazine—PTGS2—Disease—BRAF—skin cancer	1.79e-05	0.000192	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KRAS—skin cancer	1.77e-05	0.000189	CbGpPWpGaD
Mesalazine—CHUK—Disease—KRAS—skin cancer	1.63e-05	0.000175	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KRAS—skin cancer	1.6e-05	0.000172	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—skin cancer	1.52e-05	0.000163	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HRAS—skin cancer	1.5e-05	0.000161	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6—skin cancer	1.44e-05	0.000154	CbGpPWpGaD
Mesalazine—CHUK—Disease—HRAS—skin cancer	1.39e-05	0.000149	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HRAS—skin cancer	1.36e-05	0.000146	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NRAS—skin cancer	1.33e-05	0.000142	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6—skin cancer	1.33e-05	0.000142	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6—skin cancer	1.3e-05	0.00014	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NRAS—skin cancer	1.2e-05	0.000129	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KRAS—skin cancer	1.14e-05	0.000122	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NRAS—skin cancer	1.12e-05	0.00012	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KRAS—skin cancer	1.04e-05	0.000111	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—skin cancer	1.02e-05	0.000109	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HRAS—skin cancer	9.71e-06	0.000104	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KRAS—skin cancer	9.67e-06	0.000104	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6—skin cancer	9.3e-06	9.97e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—skin cancer	9.21e-06	9.87e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HRAS—skin cancer	8.81e-06	9.44e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6—skin cancer	8.43e-06	9.04e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HRAS—skin cancer	8.22e-06	8.81e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6—skin cancer	7.86e-06	8.43e-05	CbGpPWpGaD
